Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 20/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5113848 | 0.86 | KIF11 (0.71) | KIF11 | |
| SCHEMBL5555373 | 0.85 | KIF11 (0.68) | KIF11 | |
| SCHEMBL3838958 | 0.85 | KIF11 (0.44) | KIF11 | |
| SCHEMBL5112696 | 0.84 | KIF11 (0.74) | KIF11 | |
| SCHEMBL5106855 | 0.84 | KIF11 (0.65) | KIF11 | |
| SCHEMBL12393605 | 0.83 | KIF11 (0.77) | KIF11 | |
| SCHEMBL5106796 | 0.83 | KIF11 (0.83) | KIF11 | |
| SCHEMBL6515608 | 0.82 | KIF11 (0.71) | KIF11 | |
| SCHEMBL5113398 | 0.82 | KIF11 (0.74) | KIF11 | |
| SCHEMBL5365708 | 0.81 | KIF11 (0.67) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1481077-B1 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2009-11-04 | — | — | EP | claimed |
| US-7262187-B2 | Substituted oxazolo- and thizaolopyrimidinones as a mitotic kinesin inhibitor | MERCK & CO., INC. (US) | 2007-08-28 | — | — | US | claimed |
| EP-1694686-A1 | KINASE INHIBITORS | Takeda San Diego, Inc. (US) | 2006-08-30 | — | — | EP | claimed |
| EP-1481077-A4 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2006-01-11 | — | — | EP | claimed |
| US-20050171122-A1 | Mitotic kinesin inhibitors | MERCK SHARP & DOHME CORP. | 2005-08-04 | — | — | US | claimed |
| WO-2005061519-A1 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2005-07-07 | — | — | WO | claimed |
| EP-1481077-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2004-12-01 | — | — | EP | claimed |
| WO-2003049679-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2003-06-19 | — | — | WO | claimed |
| EP-1481077-B1 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2009-11-04 | — | — | EP | disclosed |
| EP-1481077-B1 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2009-11-04 | — | — | EP | disclosed |
| US-7262187-B2 | Substituted oxazolo- and thizaolopyrimidinones as a mitotic kinesin inhibitor | MERCK & CO., INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-7262187-B2 | Substituted oxazolo- and thizaolopyrimidinones as a mitotic kinesin inhibitor | MERCK & CO., INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-7262187-B2 | Substituted oxazolo- and thizaolopyrimidinones as a mitotic kinesin inhibitor | MERCK & CO., INC. (US) | 2007-08-28 | — | — | US | disclosed |
| EP-1694686-A1 | KINASE INHIBITORS | Takeda San Diego, Inc. (US) | 2006-08-30 | — | — | EP | disclosed |
| EP-1481077-A4 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20050171122-A1 | Mitotic kinesin inhibitors | MERCK SHARP & DOHME CORP. | 2005-08-04 | — | — | US | disclosed |
| WO-2005061519-A1 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2005-07-07 | — | — | WO | disclosed |
| EP-1481077-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003049679-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171122-A1 | Mitotic kinesin inhibitors | KIF5B, KIFC1, KIF2C | KIF11 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.